URGNHealthcare · BiotechnologyThe 8 Wall Street analysts covering UroGen Pharma Ltd. hold a median 12-month price target of $59 — +34.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 77 of 100 as at 7 Sept 2026 — inside the top quartile. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores UroGen Pharma Ltd. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Momentum (96): The shares have been drifting up relative to others.
Issuance (9): The company has been issuing shares or taking on financing, diluting existing holders.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on URGN, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +34.7% from it.
Of the 20 most recent actions, 5 moved their price target up and 0 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 6 Aug 2026 | Guggenheim | Maintains | Buy | $42 → $58 |
| 6 Aug 2026 | HC Wainwright & Co. | Maintains | Buy | $45 → $75 |
| 5 Aug 2026 | TD Cowen | Maintains | Buy | $50 → $60 |
| 21 July 2026 | Guggenheim | Maintains | Buy | — |
| 21 July 2026 | Guggenheim | Maintains | Buy | $32 → $42 |
| 16 July 2026 | Oppenheimer | Maintains | Outperformer | $40 → $50 |
| 16 July 2026 | Oppenheimer | Maintains | Outperformer | — |
| 3 June 2026 | HC Wainwright & Co. | Reiterates | Buy | $45 |
| 3 June 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 18 May 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 11 May 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 7 May 2026 | Oppenheimer | Maintains | Outperform | — |
| 31 Mar 2026 | D. Boral Capital | Maintains | Buy | — |
| 2 Mar 2026 | D. Boral Capital | Maintains | Buy | — |
| 23 Jan 2026 | D. Boral Capital | Maintains | Buy | — |
| 5 Jan 2026 | D. Boral Capital | Maintains | Buy | — |
| 27 Oct 2025 | D. Boral Capital | Maintains | Buy | — |
| 27 Oct 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 3 Oct 2025 | D. Boral Capital | Maintains | Buy | — |
| 19 Aug 2025 | Piper Sandler | Initiates | Overweight | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. URGN appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 8 Sept 2026, UroGen Pharma Ltd. returned +104.6% against +19.4% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 94% of US stocks
Cheaper than 13% of US stocks
Cheaper than 98% of US stocks
Cheaper than 92% of US stocks
Higher than 96% of US stocks
Higher than 90% of US stocks
Higher than 97% of US stocks
Higher than 46% of US stocks
Higher than 10% of US stocks
Higher than 97% of US stocks
Higher than 21% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
UroGen Pharma Ltd. has a market value of $2.2B and an enterprise value of $2.2B.
Revenue in the twelve months to 30 June 2026: $188.7M. The latest quarter grew 199.2% year on year.
Net income over the same four quarters: −$97.6M, a −51.7% net margin.
Diluted earnings per share, trailing twelve months: $−1.98.
Free cash flow in the twelve months to 30 June 2026: −$159.1M.
Trailing P/E: −13.9×; forward P/E: 15.8× — the forward figure prices analyst consensus estimates, not reported earnings.
UroGen Pharma Ltd. employs 300 people — $629K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own UroGen Pharma Ltd. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Zacks spotlights Oportun Financial, Uranium Royalty and Amgen, alongside standout gains from its key stock portfolios. The piece does not mention UroGen Pharma or URGN.
Why it matters — Since the article contains no reference to UroGen Pharma, it offers no direct information relevant to URGN watchers.
UroGen Pharma announced it granted inducement restricted stock units (RSUs) to 19 new employees in connection with their employment, as part of its hiring efforts. The new hires will support the commercialization of UroGen's approved products JELMYTO and ZUSDURI and the continued development of its pipeline.
Why it matters — URGN watchers may note that the company is expanding its workforce with experienced hires to support the commercialization of its approved products and the advancement of its pipeline.
UroGen Pharma Ltd. announced that it will present at upcoming investor conferences, according to a press release from its Princeton, New Jersey headquarters on September 2, 2026.
Why it matters — UroGen shareholders may be interested in the company's presentations at investor conferences, which could offer visibility into the company's pipeline and strategy.
Zacks Investment Research reports that the consensus price target for UroGen Pharma (URGN) suggests roughly 27.1% upside potential. The article notes that while this metric is not highly effective on its own, an upward trend in earnings estimate revisions could indicate near-term upside for the stock.
Why it matters — URGN watchers would care because the piece highlights both a consensus price target implying upside and a positive trend in earnings estimate revisions for the company.
UroGen Pharma and IntraGel Therapeutics entered into an equity investment agreement and a strategic Option and Research License Agreement, under which UroGen will invest up to $7 million in IntraGel. The collaboration supports the Phase 2 study of TumoCure for advanced head and neck cancer and gives UroGen access to IntraGel's biodegradable sustained-release gel platform, plus an exclusive option to acquire worldwide rights to TumoCure.
Why it matters — The agreement expands UroGen's pipeline beyond urothelial and specialty cancers by providing access to a sustained-release gel platform with potential across solid tumors and an exclusive option on the TumoCure rights.
The 8 Wall Street analysts covering UroGen Pharma Ltd. have a median 12-month price target of $59, with estimates ranging from $48 to $75. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 8 analysts covering UroGen Pharma Ltd., 7 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks UroGen Pharma Ltd. 77 out of 100 across roughly 4,600 US stocks as at 7 Sept 2026. None of this is personal advice — it does not consider your circumstances.
As at 7 Sept 2026, UroGen Pharma Ltd. ranks 77 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (96 of 100).
No one can know that. What the data says: the median 12-month target from 8 analysts implies +34.7% from the last close, and Ticker Nerd's factor model ranks UroGen Pharma Ltd. 77 out of 100 as at 7 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering UroGen Pharma Ltd. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for URGN are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $48 to $75 over the next 12 months.
UroGen Pharma Ltd. returned +104.6% over the 12 months to 8 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.
UroGen Pharma Ltd. is a biopharmaceutical company focused on developing and commercializing treatments for urothelial and specialty cancers.
The most recent item we track (Zacks Investment Research, 8 Sept 2026): "Take the Zacks Approach to Beat the Markets: Oportun Financial, Uranium Royalty & Amgen in Focus". Zacks spotlights Oportun Financial, Uranium Royalty and Amgen, alongside standout gains from its key stock portfolios. The piece does not mention UroGen Pharma or URGN.
UroGen Pharma Ltd. is a biopharmaceutical company focused on developing and commercializing treatments for urothelial and specialty cancers. The company’s current portfolio centers on its proprietary RTGel reverse-thermal hydrogel platform, which is designed to support localized drug delivery and prolonged contact with urinary tract tissue. Its marketed therapies and pipeline are built around non-surgical, organ-sparing approaches for conditions such as upper tract urothelial cancer and non-muscle invasive bladder cancer. UroGen Pharma Ltd. also advances additional investigational candidates aimed at expanding options in uro-oncology, combining drug formulation expertise with targeted delivery technologies. Headquartered in Princeton, New Jersey, with operations in Israel, the company plays a specialized role in the urology and oncology markets by focusing on treatments tailored to diseases of the urinary tract.
CEO Ms. Elizabeth A. Barrett · 300 employees · United States · https://www.urogen.com
